Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 8 Unspecified Adult Solid Tumor, Protocol Specific 1 Resectable Pancreatic Carcinoma 1 Resectable Pancreatic Cancer 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Neoplasms, Plasma Cell 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia 1 Breast Neoplasms 1 Anemia, Refractory, with Excess of Blasts 1 Anemia, Refractory 1 Adenocarcinoma of the Pancreas 1 Adenocarcinoma 1

Interventions

Oxaliplatin 32 Fluorouracil 24 Gemcitabine 23 Leucovorin 19 Docetaxel 19 pembrolizumab 17 Capecitabine 15 Radiotherapy 14 Irinotecan 13 Cisplatin 11 Bevacizumab 11 Nivolumab 8 130-nm albumin-bound paclitaxel 8 Trastuzumab 7 Erlotinib Hydrochloride 7 Cyclophosphamide 7 Albumin-Bound Paclitaxel 7 Radiosurgery 6 Paclitaxel 6 Taxes 5 S 1 (combination) 5 Metformin 5 Carboplatin 5 Blood Specimen Collection 5 Sunitinib 4 Sorafenib 4 Pemetrexed 4 Esophagectomy 4 Chemoradiotherapy 4 Cetuximab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Adenocarcinoma × paricalcitol × Clear all

NCT03415854 2026-05-12

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed

34 enrolled 11 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡